Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was down 7.1% during mid-day trading on Tuesday . The company traded as low as $5.38 and last traded at $5.87. 1,128,028 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 1,249,163 shares. The stock had previously closed at $6.32.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on TRVI. B. Riley reaffirmed a "buy" rating and set a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. HC Wainwright assumed coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, May 20th. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Trevi Therapeutics has an average rating of "Buy" and an average target price of $18.63.
Read Our Latest Stock Analysis on Trevi Therapeutics
Trevi Therapeutics Price Performance
The business's 50-day simple moving average is $6.24 and its two-hundred day simple moving average is $4.96. The stock has a market cap of $705.24 million, a price-to-earnings ratio of -16.05 and a beta of 0.59.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. Equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 18.30% of the company's stock.
Institutional Trading of Trevi Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Trevi Therapeutics by 10.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company's stock worth $113,000 after purchasing an additional 1,627 shares during the period. American Century Companies Inc. boosted its position in Trevi Therapeutics by 2.1% during the first quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock valued at $502,000 after acquiring an additional 1,653 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after acquiring an additional 2,894 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after acquiring an additional 2,935 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock worth $110,000 after acquiring an additional 3,387 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Stories
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
